Free Trial

PureTech Health (LON:PRTC) Shares Up 10.9% - Time to Buy?

PureTech Health logo with Medical background

Key Points

  • PureTech Health's share price rose 10.9% during mid-day trading, reaching GBX 118 ($1.60), significantly up from the previous close of GBX 106.40 ($1.44).
  • The company has a market cap of £287.60 million and has shown a notable increase in trading volume, with approximately 1,631,935 shares changing hands, a 120% increase over the average daily volume.
  • Insider Bharatt Chowrira purchased 167,739 shares at GBX 1 per share, indicating confidence in the company's future by the insiders, who collectively own 13.13% of the stock.
  • Interested in PureTech Health? Here are five stocks we like better.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price shot up 10.9% during trading on Friday . The stock traded as high as GBX 118 ($1.59) and last traded at GBX 118 ($1.59). 1,631,935 shares changed hands during trading, an increase of 120% from the average session volume of 740,986 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Performance

The stock has a market cap of £303.07 million, a PE ratio of 737.65 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The firm has a 50 day moving average price of GBX 129.31 and a 200 day moving average price of GBX 129.65.

Insider Activity at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were purchased at an average price of GBX 1 per share, for a total transaction of £1,677.39. Corporate insiders own 13.13% of the company's stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Further Reading

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.